What have you always wondered about the economy? Tell Us

FDA rejects Avastin for breast cancer treatment‎

Amy Scott Nov 18, 2011

Steve Chiotakis: The U.S. Food and Drug Administration said today Roche Pharmaceuticals drug Avastin has not been shown to be safe or effective for breast cancer. Marketplace’s Amy Scott is now with the latest on that story. Hey Amy.

Amy Scott: Hey.

Chiotakis: So why this ruling from the FDA?

Scott: Well the drug has dangerous side effects, including high blood pressure, bleeding, and heart failure. And it hasn’t been shown to be effective in treating breast cancer, so the FDA says those risks aren’t justified. I spoke earlier with consultant David Williams with MedPharma Partners. He says the decision is not a surprise.

David Williams: It’s been known since July 2010 that this was probably going to happen, and the recommendation was affirmed in June. So it would be a surprise if anything different had occurred.

But it’s obviously disappointing for patients who want as many treatment options as possible.

Chiotakis: Well Avastin is used to treat other cancers as well, right? How is this going to affect overall sales of the drug?

Scott: It’s used to treat certain types of colon, lung, kidney and brain cancer. And will stay on the market for those uses. So Williams says in terms of the manufacturer, he doesn’t expect a big hit.

Chiotakis: All right. Marketplace’s Amy Scott for us this morning. Amy, thanks.

Scott: You’re welcome.

Marketplace is on a mission.

We believe Main Street matters as much as Wall Street, economic news is made relevant and real through human stories, and a touch of humor helps enliven topics you might typically find…well, dull.

Through the signature style that only Marketplace can deliver, we’re on a mission to raise the economic intelligence of the country—but we don’t do it alone. We count on listeners and readers like you to keep this public service free and accessible to all. Will you become a partner in our mission today?

Your donation is critical to the future of public service journalism. Support our work today – for as little as $5 – and help us keep making people smarter.